Brentuximab vedotin as a single agent in the treatment of a pediatric primary cutaneous CD30+ lymphoproliferative disorder: A case report
- PMID: 35322542
- DOI: 10.1002/pbc.29626
Brentuximab vedotin as a single agent in the treatment of a pediatric primary cutaneous CD30+ lymphoproliferative disorder: A case report
References
REFERENCES
-
- Di Raimondo C, Parekh V, Song JY, et al. Primary cutaneous CD30+ lymphoproliferative disorders: a comprehensive review. Curr Hematol Malig Rep. 2020;15:333-342.
-
- Sauder MB, O'Malley JT, LeBoeuf NR. CD30+ lymphoproliferative disorders of the skin. Hematol Oncol Clin North Am. 2017;31:317-334.
-
- Kempf W, Pfaltz K, Vermeer MH, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011;118:4024-4035.
-
- Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703-1714. Erratum: Blood. 2019;134:1112.
-
- Stoll JR, Willner J, Oh Y, et al. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sezary syndrome. Part I: clinical and histologic features and diagnosis. J Am Acad Dermatol. 2021;85(5):1073-1090.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
